FDA Sets February 2027 Date for GHK-Cu and Melanotan-II Compounding Review
TL;DR: FDA set a Feb 2027 PCAC date for GHK-Cu and Melanotan-II compounding review, the second batch after July 2026's 7-peptide hearing.
What's New: A Confirmed Date for the Second PCAC Batch
When the FDA's Pharmacy Compounding Advisory Committee (PCAC) meets on 23–24 July 2026, it will vote on only seven of the twelve peptides that were removed from the 503A Category 2 "significant safety risk" list back in April. The remaining five — GHK-Cu (injectable routes), Melanotan II, LL-37 (Cathelicidin), DiHexa, and PEG-MGF — were held back for a separate session. Our own FDA Peptide Reclassification 2026 guide flagged this second batch as "TBD 2026" when it published on 12 June.[1]
That date is no longer open-ended. Trade-press and compounding-law coverage of the FDA's docket now reports a review window of before the end of February 2027 for this second batch, bringing the total number of compounds under active PCAC review across the two sessions to twelve.[2][3] GHK-Cu is a compound Velox Peptides stocks as an HPLC-verified research reagent, and Melanotan II is covered in our research library, which is why the update is worth tracking even though the hearing itself is more than half a year away.
Which Five Peptides Are in the February 2027 Batch?
All five were nominated to the 503A bulk-substances list, moved to Category 2, and then had those nominations formally withdrawn — the same procedural mechanism that removed BPC-157, TB-500 and the other July-batch peptides from Category 2 on 15 April 2026.[2]
| Peptide | Proposed research area | Velox coverage |
|---|---|---|
| GHK-Cu | Copper-tripeptide, dermal/tissue-remodelling research (injectable route) | In stock |
| Melanotan II | Melanocortin-receptor research | Research guide |
| LL-37 (Cathelicidin) | Antimicrobial-peptide research | Not covered |
| DiHexa | Cognitive / HGF-pathway research | Not covered |
| PEG-MGF | Pegylated mechano growth factor, tissue research | Not covered |
Neither the FDA nor the reporting we reviewed has published a formal reason for splitting the twelve into two batches. The practical effect is that GHK-Cu and Melanotan II now sit roughly seven months behind BPC-157, TB-500, MOTS-c, Semax, DSIP, Epitalon and KPV in the review queue.
How Does This Differ from the July 2026 PCAC Hearing?
Batch 1 — 23–24 July 2026
BPC-157, TB-500, KPV, MOTS-c (Day 1); DSIP/Emideltide, Semax, Epitalon (Day 2). Briefing documents are already posted; see our evidence-review guide for what FDA scientists found.
Batch 2 — by end of February 2027
GHK-Cu (injectable), Melanotan II, LL-37, DiHexa, PEG-MGF. No briefing documents have been posted yet; docket activity is expected to pick up as the review window approaches.
Both batches follow the identical procedural track: Category 2 removal (April 2026) → PCAC evidence review and public vote → a non-binding recommendation to the FDA → a possible FDA rulemaking step to add a substance to Category 1, the list that formally clears it for licensed 503A compounding. Nothing about the February 2027 date changes that sequence — it only confirms when GHK-Cu and Melanotan II will reach the evidence-review stage.
Why Is GHK-Cu Split Into Injectable and Topical Categories?
GHK-Cu's regulatory history is more fragmented than the other four peptides in this batch because the FDA has historically evaluated it differently by route of administration. Injectable GHK-Cu followed the same Category 2 nomination-and-withdrawal path as BPC-157 or TB-500. Topical/non-injectable GHK-Cu formulations, which are far more established in cosmetic-chemistry literature, sat on a separate listing track.[3]
Reporting on the docket indicates both the injectable and non-injectable questions for GHK-Cu are converging on the same February 2027 PCAC session, but the distinction matters for interpreting any eventual committee recommendation: a vote on injectable-route compounding eligibility would not automatically extend to topical use, and vice versa. Researchers tracking this compound's regulatory status should watch for which route(s) the eventual briefing documents actually cover.
What This Timeline Does — and Doesn't — Mean
What it DOES mean
GHK-Cu and Melanotan II now have a public, citable review window rather than an open-ended "subsequent PCAC session." US compounding pharmacies and researchers tracking the docket have a concrete date to plan around.
What it does NOT mean
Neither compound has been approved as a medicine, added to Category 1, or cleared for compounding. Category 2 removal is a procedural step; PCAC review is advisory; and the FDA is not obligated to follow whatever recommendation the committee eventually makes.
The same caveat applies here as with the July batch: a scheduled PCAC date is not a regulatory outcome. Given the six-and-a-half-month gap between the two sessions, it is plausible the FDA will point to the July hearing's evidence-review process — and any panel-composition controversy that emerges from it — when it eventually issues briefing documents for GHK-Cu and Melanotan II.
What Should UK Researchers Take From This?
As with the July 2026 batch, the PCAC process and 503A Category 1/2 system are US-specific mechanisms with no legal force in the UK. Nothing about this scheduling update changes the regulatory status of GHK-Cu or Melanotan II as research reagents under UK law, and neither compound is a scheduled controlled substance under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016.
Velox Peptides supplies GHK-Cu strictly as an HPLC-verified in vitro research reagent, with batch-specific certificates of analysis, independent of whatever the FDA's compounding docket ultimately decides for the US prescription-compounding market. Melanotan II is covered in our research library for background reference.
These compounds are supplied as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Velox Peptides. FDA Peptide Reclassification 2026. Published 12 June 2026. veloxpeps.com
- Frier Levitt. FDA to Remove 12 Popular Peptides from the Category 2 “Do Not Compound” List. 2026. frierlevitt.com
- Newtropin. GHK-Cu FDA Status and Compounding Update 2026. newtropin.com
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (503A Category 2 list). fda.gov
Frequently Asked Questions
When will the FDA review GHK-Cu and Melanotan-II for compounding status?
Trade-press and legal-industry reporting on FDA's compounding docket indicates a second Pharmacy Compounding Advisory Committee (PCAC) session is scheduled before the end of February 2027, covering GHK-Cu (injectable routes), Melanotan II, LL-37 (Cathelicidin), DiHexa and PEG-MGF. This is separate from the 23-24 July 2026 PCAC hearing, which covered a different seven-peptide batch.
Why weren't GHK-Cu and Melanotan-II included in the July 2026 PCAC hearing?
All twelve peptides, including GHK-Cu and Melanotan II, were removed from FDA 503A Category 2 on 15 April 2026 after their nominations were withdrawn. The FDA split the twelve into two review batches; seven went to the July 2026 PCAC hearing and the remaining five, including GHK-Cu and Melanotan II, were deferred to a session before the end of February 2027. No official reason for the split has been published.
Does removal from Category 2 mean GHK-Cu is now legal to compound?
No. Removal from Category 2 lifts the explicit "significant safety risk" designation but does not add a substance to the Category 1 list that formally permits 503A compounding. GHK-Cu and Melanotan II remain in regulatory limbo pending the PCAC's review and any subsequent FDA rulemaking.
What is the injectable-versus-topical distinction for GHK-Cu?
GHK-Cu's regulatory history separates by route of administration. Injectable GHK-Cu was nominated to and then removed from Category 2, the significant-safety-risk list. Topical/non-injectable GHK-Cu had followed a different listing path. Both routes are understood to be heading into the February 2027 PCAC review, but the FDA has historically evaluated safety risk differently for injectable versus topical use of the same molecule.
Does the FDA PCAC process affect UK research-reagent supply?
No. The PCAC and 503A Category 1/2 system governs whether US-licensed compounding pharmacies may prepare a substance for prescription dispensing under Section 503A of the US Federal Food, Drug and Cosmetic Act. It has no legal bearing on UK research-reagent supply, which is governed by the Human Medicines Regulations 2012 and MHRA guidance. Velox Peptides supplies GHK-Cu as an HPLC-verified in vitro research reagent; Melanotan II is covered in our research library.